Dexlansoprazole

Dexlansoprazole
Clinical data
Trade names	Kapidex, Dexilant, others
AHFS/Drugs.com	Monograph
MedlinePlus	a695020
License data	US DailyMed: Dexlansoprazole;
Routes of; administration	By mouth
Drug class	Proton-pump inhibitor
ATC code	A02BC06 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Excretion	50% renal and 47% in the feces
Identifiers
	IUPAC name (R)-(+)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole;
CAS Number	138530-94-6 ;
PubChem CID	9578005;
IUPHAR/BPS	5487;
ChemSpider	7852369 ;
UNII	UYE4T5I70X;
KEGG	D08903 ;
ChEMBL	ChEMBL1201863 ;
ECHA InfoCard	100.215.667
Chemical and physical data
Formula	C16H14F3N3O2S
Molar mass	369.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c2ccccc2[nH]c1[S@](=O)Cc3nccc(c3C)OCC(F)(F)F;
	InChI InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1 ; Key:MJIHNNLFOKEZEW-RUZDIDTESA-N ;
	(what is this?) (verify)

Dexlansoprazole, is a medication which reduces stomach acid. It is used to treat gastroesophageal reflux disease. Effectiveness is similar to other proton pump inhibitors (PPIs). It is taken by mouth.

Common side effects include diarrhea, abdominal pain, and nausea. Serious side effects may include osteoporosis, low blood magnesium, Clostridioides difficile infection, anaphylaxis, and pneumonia. Use in pregnancy and breastfeeding is of unclear safety. It works by blocking H⁺/K⁺-ATPase in the parietal cells of the stomach.

Dexlansoprazole was approved for medical use in the United States in 2009. In Canada in 2016, it was the most expensive Proton-pump inhibitor (PPI) available. In 2022, it was the 186th most commonly prescribed medication in the United States, with more than 2 million prescriptions.